Recent additions to Life Sciences Notes

In our most recent additions to Life Sciences Notes, we examine key issues set to affect companies as the sector continues to grapple with the challenges and opportunities of regulatory reform and geopolitics.

In North America, our teams analyse the draft US Biosecure Act, what it means for the industry and its potential to put greater pressure on global contracting agreements. In the UK, our experts examine the main parties' visions for the future of healthcare, AI, and the adoption of new technologies in the NHS alongside the potential impact of Labour's proposed Regulatory Innovation Office (RIO).

Our European team shares an overview of key EU regulatory and competition law updates - including changes to Foreign Subsidies Regulation (FSR) and enforcement trends. We are also pleased to share our contribution to the EU chapter in Lexology's Antitrust guide 'Getting the Deal Through: Pharmaceutical Antitrust'. Key topics include the Commission's investigations into anti-competitive patent strategies and abuse of dominance, as well as the Commission's first cartel infringement decision in the pharmaceutical sector. We also examine the EU's Unitary Patent Court and early trends and observations from cases brought before the court in its first year. Finally, we share an interview from Law360 who spoke with our UK Head of IP, Sebastian Moore, on his career and journey to becoming a leading life sciences lawyer.

Featured articles can be accessed via the links below.

1. Biotech in the crosshairs of global politics - the draft US Biosecure Act
2. AI In Life Sciences – What Changes To The Regulatory And Innovation Landscape Could The UK Elections Bring?
3. Overview of EU regulatory and competition law in the Pharma sector
4. Law360's 6 Questions for Sebastian Moore, HSF's UK Head of IP
5. The UPC – one year on
6. EU Foreign Subsidies Regulation – Early Enforcement Trends